Zealand Pharma CEO: "A very busy time for us"

Things are busy at Zealand Pharma, which will launch low blood sugar treatment Zegalogue in the US. According to CEO Emmanuel Dulac, the biotech company is currently delivering on its plans for the launch, and he expects to share news on glepagutide in the second quarter.

Zealand Pharma CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH

The publication of Wednesday's quarterly report allows Zealand Pharma's CEO Emmanuel Dulac to close what he calls a historical and excellent quarter.

The first three months of the year have included the biotech company's first independent approval of a drug, meaning that the low blood sugar treatment Zegalogue – which is the commercial name for dasiglucagon – will be launched in the US market at the end of June.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs